EOS 789
Alternative Names: AP-306 ; EOS-789Latest Information Update: 28 Feb 2025
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Shanghai Alebund Pharmaceuticals
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Phosphate transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Hyperphosphataemia(Combination therapy) in USA (PO)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Hyperphosphataemia(In volunteers) in Japan (PO)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Hyperphosphataemia(Monotherapy) in USA (PO)